Background
==========

Diabetes mellitus (DM) is recognized as a risk factor for the reactivation of tuberculosis (TB) infection, and relapse after therapy. Strikingly in Hispanics, the risk of DM patients of acquiring TB (25.2%) is described as comparable to that of HIV population (25.5%), taking into consideration that this population is known to have a higher diabetes prevalence when compared with other demographics ([@bib1]). Abnormal cytokine expression in diabetic patients is proposed as underlying mechanism, yet to be fully understood ([@bib2]). Still, the fact that diabetics are three times more prone to develop pulmonary TB than nondiabetics and may present with atypical imaging findings, irrespective of background incidence or geographic region, cannot be overlooked ([@bib2], [@bib3]). With DM recognized as global epidemic, and TB affecting one-third of the world population, physicians must remain vigilant ([@bib3]).

Clinical case
=============

A 45-year-old woman born in Dominican Republic (DR), with 10-year history of T2DM treated with metformin, arrived to our Urgency Room complaining of dry cough for the past 3 months. Interview also revealed unintentional 15lbs. weight loss, night sweats, occasional unquantified fever and general malaise but denied bloody sputum. She traveled to DR 2years before without any ill exposure. Surgical history was remarkable for TAH due to pelvic cancer. Physical examination showed a thin body habitus, otherwise well appearing woman with stable vital signs, presenting solely right middle lung field ronchi up on auscultation. Laboratories yielded no leukocytosis or monocytosis. Blood cultures, HIV and PPD tests were all negative. However, LDH (997units/L), ESR (80mm/h), hsCRP (71.2mg/L) and HbA1C (12.4 -- avg blood glucose 309mg/dL) were elevated. Imaging showed a right upper lobe cavitation suspicious for malignancy vs infection ([Figs 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Positive sputum for AFB disclosed active pulmonary TB in our patient, prompting therapy. Hospital course complicated with hyperglycemia despite frequent insulin dose escalation even after clearance of AFB sputum.Figure 1PA chest x-ray; right lung cavitary lesion. Figure 2Lateral chest x-ray; right upper lung cavitary lesion.

Investigation
=============

-   CXR right lung cavitary lesion with fluid levels suspicions for lung abscess.

-   LDH (997units/L), ESR (80mm/h), hsCRP (71.2mg/L) and HbA1C (12.4 -- avg blood glucose 309mg/dL) were elevated.

-   Gram stain positive for AFB.

-   Sputum culture positive for *Mycobacterium tuberculosis*.

Treatment
=========

The patient was started on four-drug regimen: ethambutol, rifampin, isoniazid and pyrazinamide, and deescalated to rifampin and isoniazid once susceptibility was available for 6months total. In addition to TB therapy, patient was treated with regular and basal Insulin requiring considerable doses to achieve DM control.

Outcome and follow-up
=====================

Patient was treated successfully and evidenced by culture-negative samples for *Mycobacterium tuberculosis* and interval resolution of cavitation on CXR. Additionally, insulin doses were reduced episodically during hospitaliza­tion and switched to oral therapy once discharged.

Discussion
==========

Diabetes is an important risk factor to consider in the evaluation of a patient with suspected pulmonary tuberculosis and even more because most patients can be overlooked and the diagnosis of TB could be missed ([@bib1]). Several atypical clinical presentations as well as radiographic imaging can differ among nondiabetic and diabetic patients with pulmonary tuberculosis that need to be understood in order to consider this serious infectious process in an otherwise 'low-risk' diabetic patient ([@bib3], [@bib4]).

DM may increase susceptibility for pulmonary TB via multiple mechanisms. Those directly related to hyperglycemia and cellular insulinopenia and the indirect effect on macrophages and lymphocytes function, leading to diminished ability to contain the TB. DM is known to affect chemotaxis, phagocytosis, activation and antigen presentation by phagocytes in response to TB. Chemotaxis of monocytes is impaired, and this defect does not improve with insulin. Studies demonstrated that DM predisposes a patient to infections in which cell-mediated immunity has a pivotal role, such as TB ([@bib4], [@bib5]).

In terms of the incidence, it is known that DM is a moderate to strong risk factor for the development of active TB. There is a 3.1 chance to have TB in DM patients compared with non-DM populations ([@bib3], [@bib6]). In the Hispanic population among 25--54years old, the risk for TB attributable to DM was 25%, equivalent to that of HIV population. However, statistical studies have shown that the prevalence of DM is greater among Hispanics (up to 18.3%) compared with Hispanics with HIV (17%) ([@bib7]). Among insulin-dependent DM (IDDM) patients, there is an increased risk for developing acute TB compared with noninsulin-dependent DM population and that HbA1C greater than 7% has a three times increased hazard of active TB compared with those with HbA1C of less than 7% ([@bib4]).

Radiological findings of TB in patients with DM not always present with the typical apical lesions seen in general population. Pulmonary TB in DM patients may present with an atypical radiological pattern and distribution particularly lower-lung involvement ([@bib4], [@bib6]). Clinically, it is important because lower lobe TB may be misdiagnosed as community-acquired pneumonia or even lung cancer. Also, patients with pulmonary TB that do not have upper lobe involvement are less likely to have positive sputum smears; therefore, other diagnostic methods for pulmonary TB should be considered such as bronchoalveolar lavage and transbroncheal biopsy, among others ([@bib4], [@bib8]). Clinicians should be aware of this atypical presentation when dealing with suspected TB on diabetic patients in order to make a precise diagnosis.

As per TB treatment, time to negative sputum cultures is longer among DM patients compared with control. In terms of the drugs used to treat TB, they can worsen glycemic control in patients with DM. Rifampin is a powerful inducer of host cytochrome P450 and, therefore, on IDDM patients; insulin requirements may increase during Rifampin therapy. Oral hypoglycemic drugs such as sulfonylureas are also affected by rifampin metabolism and could cause hyperglycemia making the whole process a vicious cycle between illness, body metabolism, diabetes mellitus and its respective treatments one affecting another ([@bib4]).

Our case portrays that the consideration of TB as differential diagnosis in diabetics should be exercised with the same strength, as it is undertaken during the evaluation of HIV patients. Inability to recognize TB will endanger the patient, hospital dwellers and staff, and perpetuate this global public health menace.
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